Personalis, Inc. (NASDAQ:PSNL) Given Consensus Rating of “Hold” by Brokerages

Personalis, Inc. (NASDAQ:PSNL) has been given an average recommendation of “Hold” by the ten brokerages that are presently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, four have given a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $14.5357.

A number of equities research analysts have recently weighed in on PSNL shares. Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a research note on Friday, July 17th. TD Cowen reiterated a “buy” rating on shares of Personalis in a research report on Wednesday, July 15th. Needham & Company LLC downgraded shares of Personalis from a “buy” rating to a “hold” rating in a research note on Monday, July 20th. BTIG Research raised their target price on shares of Personalis from $11.00 to $16.25 and gave the company a “buy” rating in a research report on Monday, July 20th. Finally, Lake Street Capital cut shares of Personalis from a “buy” rating to a “hold” rating and set a $16.25 target price on the stock. in a research note on Monday, July 20th.

Insider Buying and Selling at Personalis

In other Personalis news, CEO Christopher M. Hall sold 100,000 shares of the stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $15.08, for a total value of $1,508,000.00. Following the completion of the transaction, the chief executive officer directly owned 235,986 shares in the company, valued at approximately $3,558,668.88. This trade represents a 29.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 4,982 shares of Personalis stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $14.00, for a total value of $69,748.00. Following the sale, the chief financial officer directly owned 198,833 shares in the company, valued at $2,783,662. The trade was a 2.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 256,233 shares of company stock worth $3,568,236. 4.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd boosted its position in Personalis by 76.1% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock worth $27,000 after buying an additional 1,479 shares during the period. Legal & General Group Plc acquired a new position in Personalis in the 2nd quarter valued at approximately $30,000. International Assets Investment Management LLC bought a new position in shares of Personalis during the fourth quarter valued at $31,000. BNP Paribas Financial Markets raised its stake in shares of Personalis by 406.4% during the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after acquiring an additional 5,177 shares during the last quarter. Finally, Focus Partners Wealth acquired a new position in shares of Personalis during the first quarter worth $47,000. Institutional investors and hedge funds own 61.91% of the company’s stock.

Personalis Price Performance

Shares of NASDAQ:PSNL opened at $16.60 on Wednesday. Personalis has a 1 year low of $4.95 and a 1 year high of $18.89. The stock has a market capitalization of $1.74 billion, a price-to-earnings ratio of -15.23 and a beta of 2.31. The company’s 50 day simple moving average is $14.68 and its 200 day simple moving average is $10.41.

Personalis (NASDAQ:PSNL) last released its earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.04). Personalis had a negative return on equity of 46.47% and a negative net margin of 153.84%.The business had revenue of $22.36 million for the quarter, compared to the consensus estimate of $16.69 million. As a group, analysts anticipate that Personalis will post -1.07 EPS for the current fiscal year.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.